HPV HANDBOOK - Zervita

More documents

Recommendations

Info

Indexadenocarcinoma,detection by HPV testing 31sensitivity of Pap smear for 13administration required for screeningprogrammes 46age,effects on SIL progression andregression 68HPV infection,patterns of and 67peaks and 27HPV testing and 26incidence of cervical cancer and 27algorithm for screening 46, 47ALTS study 53key features of, 54anxiety,caused by screening programmes 48unnecessary treatments and 36ASCUS, see under atypical squamouscells of undetermined significanceASCUS/Low-grade squamousintraepithelial lesions Triage Study(ALTS) 53atypical squamous cells of undeterminedsignificance (ASCUS) 40American cf European 54recommendations for ASCUSpositive HPV-negative women 54surveillance of 40use of HPV testing for triage in 53automated screening procedures 52Autopap 52Belgium,mortality and incidence in 17screening policy 16benefits of screening 48borderline and mild dyskaryosis (BMD),triage of women with 28regression of 37risk assessment in 28Canada, screening policy 16cancerous lesions, identification by Papsmear 14cervical cancer,age-standardized rates of 15cumulative risk 19effect of varying vaccine coverage on72effects of vaccination on incidence70, 74in young women 27incidence 12, 36model results for 69mortality 12pathogenesis and HPV infection 26screening and public health 45–58cervical intraepithelial neoplasia, seeunder CINchimeric vaccines 62China, HPV testing plus cytology studiesin 31CIN 1 lesions,regression of 36surveillance of 40CIN 2 lesions, regression of 36CIN 3 lesions, identification by HPVtesting 36CIN lesions,follow-up after treatment 56HPV genotypes and risk of 38regression of 27clinical trial endpoints for vaccines 73colposcopy referral rates in Finland 13computer-based slide analysis 52computerized call–recall system in UK 18cost,estimates of 50life-years saved 50of HPV vaccine 75cost-effectiveness,balancing the benefits anddrawbacks of screening 4879
3: HPV AND CERVICAL CANCER: PUBLIC HEALTH PERSPECTIVESlife-years saved 50of automated screening procedures 52of HPV testing as primary screening 56of HPV testing in women >30 years 32of HPV-based triage 53of LBC 51screening frequency and 50screening in young women 27Costa Rica, HPV testing plus cytologystudies in 31cumulative risk 19cure, confirmation by HPV testing 31, 56cytology,as a screening test 11–20rationale for use in screening 12suspicious or borderline 14use after positive HPV test 29Denmark,mortality and incidence in 17, 18screening policy 16drawbacks of screening 48effectiveness,of Pap smear 49of screening programmes 46of vaccines 65see also cost-effectivenesssensitivity and specificity and 49efficacy of vaccines 65England(UK), screening policy in 16European Commission, recommendationsfrom 15false-positives in screening programmes 48Finland,cervical cancer incidence andmortality in 12mortality and incidence in 17referral rates for colposcopy in 13screening policy 16France,mortality and incidence in 17screening policy 16gender, vaccination of men 66Germany,mortality and incidence in 17screening policy 16Greece,mortality and incidence in 17screening policy 16high-grade lesions, sensitivity of Papsmear for 13HPV (human papillomavirus),incidence 36infection and cervical cancerpathogenesis 26natural history of infection 26HPV genotypes 26risk of CIN lesions and 38HPV infection,cost and purpose of vaccine 75early natural history of 37increased risk 37natural history in men 66natural history in women 66outcomes in men cf women 67progression to SIL 68role in cervical cancer 63transient nature of lesions 36transition to high-grade dyskaryosis 49vaccination of men 66HPV testing,as a screening test 25–32as primary screening 55characteristics of 25correlation with cytology 38cost-effectiveness as triage 53cost-effectiveness of 32disadvantages as a screening test35–41followed by cytology 29for cure confirmation 56frequency 30high negative predictive value 54, 56in women >40 years 39persistence of infection 55poor specificity of 55role in women >30 years 29role in young women 27specificity of 39to detect adenocarcinoma 31to identify CIN 3 lesions 36unnecessary treatments and anxietyafter 36use as triage 5280
Page 4 and 5:
THE HEALTH PROFESSIONAL’SHPV HAND
Page 6:
ContentsList of contributors 7Intro
Page 10:
Introduction to the HPV Handbook se
Page 13 and 14:
3: HPV AND CERVICAL CANCER: PUBLIC
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 26 and 27:
2. HPV testing as a screeningtest:
Page 28 and 29:
HPV TESTING AS A SCREENING TEST: TH
Page 30 and 31: HPV TESTING AS A SCREENING TEST: TH
Page 36 and 37: 3. HPV testing as a screeningtest:
Page 44: HPV TESTING AS A SCREENING TEST: TH
Page 47 and 48: 3: HPV AND CERVICAL CANCER: PUBLIC
Page 66 and 67: THE POTENTIAL PUBLIC HEALTH IMPACT
Page 82 and 83: INDEXuse in ASCUS 53use to confirm
show all

HPV HANDBOOK - Zervita

Create successful ePaper yourself

Delete template?

Save as template?